



NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

[Click here to Listen](#)

Episode Description: The NRG Oncology Podcast co-hosts discuss the currently active & accruing NRG-GU012 study, also known as the "SAMURAI" study. This study is assessing if stereotactic ablative radiotherapy to the primary tumor in combination with immunotherapy improves outcomes when compared to immunotherapy by itself for patients who have metastatic, unresected, renal cell carcinoma.



All episodes of The NRG Oncology Podcast can be found on Spotify, Apple Music, YouTube, & Amazon or you can stream them directly from our website at

www.NRGOncology.org/Podcast